866-997-4948(US-Canada Toll Free)

Chemotherapy Induced Anemia Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Mar 2013

Category :

Oncology

No. of Pages : 53 Pages


Global Markets Directs, \'Chemotherapy Induced Anemia Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Chemotherapy Induced Anemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Anemia. 

Chemotherapy Induced Anemia Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Chemotherapy Induced Anemia.
  • A review of the Chemotherapy Induced Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Chemotherapy Induced Anemia pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Anemia.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Anemia pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Chemotherapy Induced Anemia Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Chemotherapy Induced Anemia 8
Chemotherapy Induced Anemia Therapeutics under Development by Companies 10
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Pre-Clinical Stage Products 15
Comparative Analysis 15
Chemotherapy Induced Anemia Therapeutics Products under Development by Companies 16
Companies Involved in Chemotherapy Induced Anemia Therapeutics Development 17
Eli Lilly and Company 17
Reliance Life Sciences Pvt. Ltd. 18
3SBio Inc. 19
ProMetic Life Sciences Inc. 20
Lipoxen PLC 21
Avesthagen Limited 22
Therapure Biopharma Inc. 23
Chemotherapy Induced Anemia Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
NuPIAO - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
EPIAO - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
PBI-1402 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ErepoXen - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
darbepoetin alfa biosimilar - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
LY-2787106 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
PanCyte - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
erythropoietin biosimilar - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
TBI-304 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
darbepoetin alfa - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
TP-0413 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Chemotherapy Induced Anemia Therapeutics Drug Profile Updates 41
Chemotherapy Induced Anemia Therapeutics Discontinued Products 44
Chemotherapy Induced Anemia Therapeutics - Dormant Products 45
Chemotherapy Induced Anemia Product Development Milestones 46
Featured News & Press Releases 46
Jan 31, 2012: Kyowa Hakko Kirin Withdraws Domestic Application For Additional Chemotherapy-Induced Anemia Indication For NESP 46
Jul 11, 2011: 3SBio Receives SFDA Approval For High-Dose EPIAO 46
Jun 02, 2011: Acceleron And Celgene Initiate Phase II/III Study Of ACE-011 To Treat Chemotherapy-Induced Anemia In Patients With Lung Cancer 47
Sep 30, 2010: Safety study for subcutaneous epoetin alfa biosimilar Binocrit/Epoetin alfa Hexal/Abseamed suspended 47
Jun 06, 2010: Alder\'s ALD518 Antibody Therapeutic Reduces Disease Symptoms, Anemia In Phase IIa Clinical Trial In NSCLC Patients 48
Mar 02, 2010: Lipoxen Initiates Phase II Trial Of ErepoXen In India 49
Feb 22, 2010: Retacrit Received a Positive Opinion From the European Committee for Medicinal Products for Human Use (CHMP) for Subcutaneous (SC) use in Renal Anaemia 49
Dec 01, 2009: Acceleron Pharma To Present Clinical Trial Results Of ACE-011 At The 51st Annual Meeting Of The American Society Of Hematology 49
Jul 28, 2009: Acceleron and Celgene Initiate Phase II Study of ACE-011 to Treat Chemotherapy-Induced Anemia 50
May 06, 2009: Lipoxen Plc Announces Positive Phase I Clinical Trial Results For ErepoXen 50

Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 53
Disclaimer 53

List of Table


Number of Products Under Development for Chemotherapy Induced Anemia, H1 2013 8
Products under Development for Chemotherapy Induced Anemia Comparative Analysis, H1 2013 9
Number of Products under Development by Companies, H1 2013 11
Comparative Analysis by Late Stage Development, H1 2013 12
Comparative Analysis by Mid Clinical Stage Development, H1 2013 13
Comparative Analysis by Early Clinical Stage Development, H1 2013 14
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 15
Products under Development by Companies, H1 2013 16
Eli Lilly and Company, H1 2013 17
Reliance Life Sciences Pvt. Ltd., H1 2013 18
3SBio Inc., H1 2013 19
ProMetic Life Sciences Inc., H1 2013 20
Lipoxen PLC, H1 2013 21
Avesthagen Limited, H1 2013 22
Therapure Biopharma Inc., H1 2013 23
Assessment by Monotherapy Products, H1 2013 24
Assessment by Stage and Route of Administration, H1 2013 26
Assessment by Stage and Molecule Type, H1 2013 28
Chemotherapy Induced Anemia Therapeutics Drug Profile Updates 41
Chemotherapy Induced Anemia Therapeutics Discontinued Products 44
Chemotherapy Induced Anemia Therapeutics Dormant Products 45

List of Chart


Number of Products under Development for Chemotherapy Induced Anemia, H1 2013 8
Products under Development for Chemotherapy Induced Anemia Comparative Analysis, H1 2013 9
Products under Development by Companies, H1 2013 10
Late Stage Products, H1 2013 12
Mid Clinical Stage Products, H1 2013 13
Early Clinical Stage Products, H1 2013 14
Pre-Clinical Stage Products, H1 2013 15
Assessment by Monotherapy Products, H1 2013 24
Assessment by Route of Administration, H1 2013 25
Assessment by Stage and Route of Administration, H1 2013 26
Assessment by Molecule Type, H1 2013 27
Assessment by Stage and Molecule Type, H1 2013 28

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *